Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …

Highlights•Acquired resistance mechanisms to osimertinib can be EGFR dependent or
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …

Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …

Introduction: The effect of local ablative therapy (LAT) for oligoprogressive epidermal growth
factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) remains undetermined …

Oncogene-driven non small cell lung cancer (NSCLC) is a distinct entity in thoracic
oncology. The availability of effective target therapies, like EGFR inhibitors or ALK inhibitors …

Oligoprogression in non-small cell lung cancer: a narrative review - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

Thoracic radiation therapy (RT) for non-small cell lung cancers may overcome resistance to
tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis …